Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Drug Safety
Erschienen in: Drug Safety 13/2001

01.11.2001 | Practical Drug Safety

Treating Epilepsy in the Elderly

Safety Considerations

verfasst von: Dr Santiago Arroyo, Günter Kramer

Erschienen in: Drug Safety | Ausgabe 13/2001

Einloggen, um Zugang zu erhalten

Abstract

The incidence of epilepsy increases with advancing age. Epilepsy in the elderly has different aetiologies from that in younger populations, cerebrovascular disease being the most common condition associated with seizures. Partial seizures are the predominant seizure type in older patients. A diagnosis of epilepsy in the elderly is based mainly on the history and is frequently delayed. In addition, seizure imitators are especially frequent. In many cases ancillary tests for diagnosis may show normal age-related variants, sometimes making results difficult to interpret. Treating epilepsy in the elderly is problematic due to a number of issues that relate to age and comorbidity. The physical changes associated with increasing age frequently lead to changes in the pharmacokinetics of many anticonvulsants. The treatment of epilepsy in the elderly is also complicated by the existence of other diseases that might affect the metabolism or excretion of anticonvulsants and the presence of concomitant medications that might interact with them. Moreover, specific trials of anticonvulsants in the aged population are scarce. General guidelines for treatment include starting at lower doses, slowing the titration schedule, individualising the choice of anticonvulsant to the characteristics of the patient, avoiding anticonvulsants with important cognitive or sedative adverse effects, and where possible, treating with monotherapy.
Literatur
1.
Annegers JF, Hauser WA, Lee R-J, et al. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935–1984. Epilepsia 1995; 36: 32–33
2.
Loiseau J, Loiseau P, Duché B, et al. A survey of epileptic disorders in southwest France: seizures in elderly patients. Ann Neurol 1990; 27: 232–7PubMedCrossRef
3.
Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34: 453–68PubMedCrossRef
4.
Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352: 1970–3PubMedCrossRef
5.
Forsgren L, Bucht G, Eriksson S, et al. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia 1996; 37: 224–9PubMedCrossRef
6.
Olafsson E, Hauser WA, Ludvigsson P, et al. Incidence of epilepsy in rural Iceland: a population-based study. Epilepsia 1996; 37: 951–5PubMedCrossRef
7.
Hauser WA, Annegers JF, Kurland AH. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 1991; 32: 429–45PubMedCrossRef
8.
de la Court A, Breteler MMB, Meinardi H, et al. Prevalence of epilepsy in the elderly: the Rotterdam study. Epilepsia 1996; 37: 141–7PubMedCrossRef
9.
Keranen T, Sillanpaa M, Riekkinen PJ. Distribution of seizure types in an epileptic population. Epilepsia 1988; 29: 1–7PubMedCrossRef
10.
Fisher RS, Webber WR, Lesser RP, et al. High-frequency EEG activity at the start of seizures. J Clin Neurophysiol 1992; 9: 441–8PubMedCrossRef
11.
Gram L, Alving J, Sagild JC, et al. Juvenile myoclonic epilepsy in unexpected age groups. Epilepsy Res 1988; 2(2): 137–40PubMedCrossRef
12.
Grunewald RA, Panayiotopoulos CP. Diagnosing juvenile myoclonic epilepsy in an elderly patient. Seizure 1994; 3: 239–41PubMedCrossRef
13.
Nishiura N, Oiwa T. Epilepsy above 70 years of age — four cases with spike and wave complex. Folia Psychiatr Neurol Jpn 1979; 33(3): 263–8PubMed
14.
Loiseau J, Crespel A, Picot MC, et al. Idiopathic generalized epilepsy of late onset. Seizure 1998; 7: 485–7PubMedCrossRef
15.
Li X, Breteler MM, de Bruyne MC, et al. Vascular determinants of epilepsy: the Rotterdam Study. Epilepsia 1997; 38: 1216–20PubMedCrossRef
16.
Berges S, Moulin T, Berger E, et al. Seizures and epilepsy following strokes: recurrence factors. Eur Neurol 2000; 43: 3–8PubMedCrossRef
17.
Arboix A, Garcia-Eroles L, Massons JB, et al. Predictive factors of early seizures after acute cerebrovascular disease. Stroke 1997; 28: 1590–4PubMedCrossRef
18.
Reith J, Jorgensen HS, Nakayama H, et al. Seizures in acute stroke: predictors and prognostic significance. The Copenhagen Stroke Study. Stroke 1997; 28: 1585–9PubMedCrossRef
19.
Burn J, Dennis M, Bamford J, et al. Epileptic seizures after a first stroke: the Oxfordshire community stroke project. BMJ 1997; 315: 1582–7PubMedCrossRef
20.
So EL, Annegers JF, Hauser WA, et al. Population-based study of seizure disorders after cerebral infarction. Neurology 1996; 46: 350–5PubMedCrossRef
21.
Faught E, Peters D, Bartolucci A, et al. Seizures after primary intracerebral hemorrhage. Neurology 1989; 39: 1089–93PubMedCrossRef
22.
Shinton RA, Gill JS, Zezulka AV, et al. The frequency of epilepsy preceding stroke,case-control study in 230 patients. Lancet 1987; 11–3
23.
Hesdorffer DC, Hauser WA, Annegers JF, et al. Severe, uncontrolled hypertension and adult-onset seizures: a case- control study in Rochester, Minnesota. Epilepsia 1996; 37: 736–41PubMedCrossRef
24.
Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology 1996; 46: 727–30PubMedCrossRef
25.
Hauser WA, Morris ML, Heston LL, et al. Seizures and myoclonus in patients with Alzheimer’s disease. Neurology 1986; 36: 1226–30PubMedCrossRef
26.
Lowry JK, Snyder JJ, Lowry PW. Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch Neurol 1998; 55: 922–8PubMedCrossRef
27.
Ng SK, Hauser WA, Brust JC, et al. Alcohol consumption and the risk of new onset seizure. N Engl J Med 1988; 319: 666–73PubMedCrossRef
28.
Harden CL, Rosenbaum DH, Daras M. Hyperglycemia presenting with occipital seizures. Epilepsia 1991; 32: 215–20PubMedCrossRef
29.
Askenasy JJ, Streifler M, Carasso R. Moderate nonketotic hyperglycemia — a cause of focal epilepsy. Report of two cases and review of literature. Eur Neurol 1977; 16: 51–61PubMedCrossRef
30.
Spitz MC, Bainbride JL, Ramsay ER, et al. Observations on the delay in the diagnosis of seizures in the elderly [abstract]. Epilepsia 2000; 41Suppl. 7: 109
31.
Drury I, Beydoun A. Pitfalls of EEG interpretation in epilepsy. Neurol Clin 1993; 11: 857–81PubMed
32.
Santamaria J, Chiappa KH. The EEG of drowsiness in normal adults. J Clin Neurophysiol 1987; 4: 327–82PubMedCrossRef
33.
Drury I, Beydoun A. Interictal epileptiform activity in elderly patients with epilepsy. Electroencephalogr Clin Neurophysiol 1998; 106: 369–73PubMedCrossRef
34.
Drury I, Selwa LM, Schuh LA, et al. Value of inpatient diagnostic CCTV-EEG monitoring in the elderly. Epilepsia 1999; 40: 1100–2PubMedCrossRef
35.
van Donselaar CA, Geerts AT, Schimsheimer RJ. Idiopathic first seizure in adult life: who should be treated? BMJ 1991; 302: 620–3PubMedCrossRef
36.
Schreiner A, Pohlmann-Eden B, Schwartz A, et al. Epileptic seizures in subcortical vascular encephalopathy. J Neurol Sci 1995; 130: 171–7PubMedCrossRef
37.
Taveras JM. Nuclear magnetic resonance imaging. AJR Am J Roentgenol 1982; 139(2): 406–7PubMed
38.
Hesdorffer DC, Logroscino G, Cascino G, et al. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology 1998; 50: 735–41PubMedCrossRef
39.
Coeytaux A, Jallon P, Galobardes B, et al. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 2000; 55: 693–7PubMedCrossRef
40.
Rumbach L, Sablot D, Berger E, et al. Status epilepticus in stroke: report on a hospital-based stroke cohort. Neurology 2000; 54: 350–4PubMedCrossRef
41.
Waterhouse EJ, Vaughan JK, Barnes TY, et al. Synergistic effect of status epilepticus and ischemic brain injury on mortality. Epilepsy Res 1998; 29: 175–83PubMedCrossRef
42.
Allcock LM, O’Shea D. Diagnostic yield and development of a neurocardiovascular investigation unit for older adults in a district hospital. J Gerontol A Biol SciMed Sci 2000; 55(8): M458–62CrossRef
43.
44.
Zucconi M, Ferini-Strambi L. NREM parasomnias: arousal disorders and differentiation from nocturnal frontal lobe epilepsy. Clin Neurophysiol 2000 Sep; 111Suppl. 2: S129–35PubMedCrossRef
45.
Fakhoury T, Abou-Khalil B, Newman K. Psychogenic seizures in old age: a case report. Epilepsia 1993 Nov-Dec; 34(6): 1049–51PubMedCrossRef
46.
Ochs HR, Otten H, Greenblatt DJ, et al. Diazepam absorption: effects of age, sex, and Billroth gastrectomy. Dig Dis Sci 1982; 27(3): 225–30PubMedCrossRef
47.
Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc 1979; 27(1): 20–2PubMed
48.
Koyama H, Sugioka N, Uno A, et al. Age-related alteration of carbamazepine-serum protein binding in man. J Pharm Pharmacol 1999; 51: 1009–14PubMedCrossRef
49.
Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet 1988; 15(5): 287–94PubMedCrossRef
50.
Nolan L, O’Malley K. Prescribing for the elderly. Part I: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 362): 142–9PubMed
51.
Pryor FM, Ramsay DA, Rowan AJ, et al. Diagnostic, demographic and retention issues in managing seizures in older adults [abstract]. Neurology 2000; 54Suppl. 3: A84–5
52.
Geddes JW, Ulas J, Brunner LC, et al. Hippocampal excitatory amino acid receptors in elderly, normal individuals and those with Alzheimer’s disease: non-N-methyl-D-aspartate receptors. Neuroscience 1992; 50: 23–34PubMedCrossRef
53.
Faught E. Epidemiology and drug treatment of epilepsy in elderly people. Drugs Aging 1999; 15: 255–69PubMedCrossRef
54.
Macdonald RL, Kelly, KM. Antiepileptic drug mechanisms of action. Epilepsia 1995: 32Suppl. 2; S2–12CrossRef
55.
Bertilsson L, Tomson T, Tybring G. Pharmacokinetics: time-dependent changes — autoinduction of carbamazepine epoxidation. J Clin Pharmacol 1986; 26: 459–62PubMed
56.
Westenberg HG, van der Kleijn E, Oei TT, et al. Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. Clin Pharmacol Ther 1978; 23: 320–8
57.
Hockings N, Pall A, Moody J, et al. The effects of age on carbamazepine pharmacokinetics and adverse effects. Br J Clin Pharmacol 1986; 22: 725–8PubMedCrossRef
58.
Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–51PubMedCrossRef
59.
Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiat 1995; 58: 44–50PubMedCrossRef
60.
Callaghan N, Kenny RA, O’Neill B, et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiat 1985; 48: 639–44PubMedCrossRef
61.
Richens A, Davidson DL, Cartlidge NE, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiat 1994; 57: 682–7PubMedCrossRef
62.
Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327: 765–71PubMedCrossRef
63.
Troupin A, Moretti Ojemman L, Halpern L, et al. Carbamazepine — a double-blind comparison with phenytoin. Neurology 1977; 27: 511–9PubMedCrossRef
64.
Kalviainen R, Aikia M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. Arandomized, controlled study. ArchNeurol 1995; 52: 989–96
65.
Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70–6PubMedCrossRef
66.
Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81–7PubMedCrossRef
67.
Van Amelsvoort T, Bakshi R, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181–8PubMedCrossRef
68.
Takayanagi K, Hisauchi I, Watanabe J, et al. Carbamazepine-induced sinus node dysfunction and atrioventricular block in elderly women. Jpn Heart J 1998; 39: 469–79PubMedCrossRef
69.
Umstead GS, Morales M, McKercher PL. Comparison of total, free, and salivary phenytoin concentrations in geriatric patients. Clin Pharm 1986; 5: 59–62PubMed
70.
Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982; 31(3): 301–4PubMedCrossRef
71.
Anderson GD, Pak C, Doane KW, et al. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother 1997; 31: 279–84PubMed
72.
Reidenberg MM, Odar-Cederlof I, von Bahr C, et al. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 1971; 285(5): 264–7PubMedCrossRef
73.
Turnbull DM, Howel D, Rawlins MD, et al. Which drug for the adult epileptic patient: phenytoin or valproate? BMJ Clin Res Ed 1985; 290: 815–9CrossRef
74.
Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double- blind comparison with phenytoin. Epilepsia 1999; 40: 601–7PubMedCrossRef
75.
Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia 1990; 31: 584–91PubMedCrossRef
76.
Tjellesen L, Gotfredsen A, Borg J, et al. Relationship between local and total body bone mineral in epileptic patients and normal subjects. Clin Physiol 1983; 3: 359–64PubMedCrossRef
77.
Christiansen C, Rodbro P, Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. BMJ 1973; 4: 695–701PubMedCrossRef
78.
Martines C, Gatti G, Sasso E, et al. The disposition of primidone in elderly patients. Br J Clin Pharmacol 1990; 30(4): 607–11PubMedCrossRef
79.
Bryson SM, Verma N, Scott PJ, et al. Pharmacokinetics of valproic acid in young and elderly subjects. Br J Clin Pharmacol 1983; 16(1): 104–5PubMedCrossRef
80.
Duncan JS, Patsalos PN, Shorvon SD. Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication. Epilepsia 1991; 32: 101–15PubMedCrossRef
81.
Fleitman JS, Bruni J, Perrin JH, et al. Albumin-binding interactions of sodium valproate. J Clin Pharmacol 1980; 20: 514–7PubMed
82.
Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141–6PubMedCrossRef
83.
Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000; 55: 588–91PubMedCrossRef
84.
Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997; 24: 240–4PubMed
85.
Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47: 626–35PubMedCrossRef
86.
Isojarvi JI, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–51PubMedCrossRef
87.
Read CL, Stephen LJ, Stolarek IH, et al. Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study. Seizure 1998; 7: 159–62PubMed
88.
Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive functioning. Comparison with carbamazepine. The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol 1996; 53: 1008–16PubMedCrossRef
89.
Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994; 35: 381–90PubMedCrossRef
90.
Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol 1979; 7Suppl. 1: 51S–7PubMedCrossRef
91.
Bernus I, Dickinson RG, Hooper WD, et al. Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations. Drugs Aging 1997; 10(4): 278–89PubMedCrossRef
92.
Greenblatt DJ, Allen MD, Locniskar A, et al. Lorazepam kinetics in the elderly. Clin Pharmacol Ther 1979; 26(1): 103–13PubMed
93.
Lechin F, Van der Dijs B, Benaim M. Benzodiazepines: tolerability in elderly patients. Psychother Psychosom 1996; 65(4): 171–82PubMedCrossRef
94.
Foy A, O’Connell D, Henry D, et al. Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol A Biol Sci Med Sci 1995; 50(2): M99–106PubMedCrossRef
95.
Kruse WH. Problems and pitfalls in the use of benzodiazepines in the elderly. Drug Saf 1990; 5(5): 328–44PubMedCrossRef
96.
Trewin VF, Lawrence CJ, Veitch GB. An investigation of the association of benzodiazepines and other hypnotics with the incidence of falls in the elderly. J Clin Pharm Ther 1992; 17(2): 129–33PubMedCrossRef
97.
Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018–25PubMedCrossRef
98.
Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997; 337: 1807–12PubMedCrossRef
99.
Binnie CD, Debets RM, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989; 4: 222–9PubMedCrossRef
100.
Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457–65PubMedCrossRef
101.
Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535–41PubMedCrossRef
102.
Wootton R, Soul-Lawton J, Rolan PE, et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 1997; 43(1): 23–7PubMedCrossRef
103.
Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23: 149–55PubMedCrossRef
104.
Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476–9PubMedCrossRef
105.
Giorgi L, Gomez G, O’Neill F, et al. The tolerability of lamotrigine in elderly patients with epilepsy. Drugs Aging 2001; 18(8): 621–30PubMedCrossRef
106.
Messenheimer J, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18: 281–96PubMedCrossRef
107.
Messenheimer JA, Guberman AH. Rash with lamotrigine: dosing guidelines. Epilepsia 2000; 41(4): 488PubMedCrossRef
108.
Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999; 33(10): 1037–42PubMedCrossRef
109.
Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998; 55: 437–60PubMedCrossRef
110.
Snel S, Jansen JA, Mengel HB, et al. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy. J Clin Pharmacol 1997; 37: 1015–20PubMed
111.
Samara EE, Gustavson LE, El Shourbagy T, et al. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia 1998; 39: 868–73PubMedCrossRef
112.
Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997; 38: 445–51PubMedCrossRef
113.
So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995; 22: 221–6PubMedCrossRef
114.
Ben-Menachem E. International experience with tiagabine addon therapy. Epilepsia 1995; 36Suppl. 6: S14–21PubMedCrossRef
115.
Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995; 36Suppl. 6: S2–6PubMedCrossRef
116.
Brodie MJ, Bomhof MAM, Kälviäinen R. Double-blind comparison of tiagabine and carbamazepine monotherapy in newly diagnosed epilepsy [abstract]. Epilepsia 1997; 38Suppl. 3: 66
117.
118.
Leppik IE, Gram L, Deaton R, et al. Safety of tiagabine: summary of 53 trials. Epilepsy Res 1999; 33: 235–46PubMedCrossRef
119.
Balslev T, Uldall P, Buchholt J. Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients. Eur J Paediatr Neurol 2000; 4: 169–70PubMedCrossRef
120.
Trinka E, Moroder T, Nagler M, et al. Clinical and EEG findings in complex partial status epilepticus with tiagabine. Seizure 1999; 8: 41–4PubMedCrossRef
121.
Schapel G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure 1996; 5: 153–6PubMed
122.
Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39: 33–42PubMedCrossRef
123.
Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000; 41Suppl. 1: S61–5PubMedCrossRef
124.
Abou-Khalil B. Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group. Epilepsia 2000; 41Suppl. 1: S72–6PubMedCrossRef
125.
Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41Suppl. 1: S66–71PubMedCrossRef
126.
Reife RA, Pledger GW. Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997; 38Suppl. 1: S31–3PubMedCrossRef
127.
Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52: 321–7PubMedCrossRef
128.
Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41(9): 1167–78PubMedCrossRef
129.
Petroff OA, Rothman DL, Behar KL, et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39: 95–9PubMedCrossRef
130.
Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409–27PubMedCrossRef
131.
Muscas GC, Chiroli S, Luceri F, et al. Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. Seizure 2000; 9: 47–50PubMedCrossRef
132.
Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. Neurology 1997; 49: 739–45PubMedCrossRef
133.
Beydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology 1997; 49: 746–52PubMedCrossRef
134.
The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double blind, placebocontrolled, parallel-group study. Neurology 1993; 43: 2292–8
135.
Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998; 51: 1282–8PubMedCrossRef
136.
Marson AG, Kadir ZA, Hutton JL, et al. Gabapentin for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000; (2): CD001415PubMed
137.
138.
DeToledo JC, Toledo C, DeCerce J, et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997; 19: 394–6PubMedCrossRef
139.
Martin R, Meador K, Turrentine L, et al. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia 2001; 42(6): 764–71PubMedCrossRef
140.
McLean MJ, Schmutz M, Wamil AW, et al. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35:Suppl. 3: S5–9PubMedCrossRef
141.
Isojarvi JI, Pakarinen AJ, Rautio A, et al. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994; 35: 1217–20PubMedCrossRef
142.
Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35:Suppl. 3: S10–3PubMedCrossRef
143.
Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35Suppl. 3: S14–9PubMedCrossRef
144.
May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21: 175–81PubMedCrossRef
145.
Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 1996; 29: 156–8PubMedCrossRef
146.
Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. Psychopharmacology Berl 1994; 116: 115–6PubMedCrossRef
147.
van Heiningen PN, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410–9PubMedCrossRef
148.
Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: doubleblind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52: 732–7PubMedCrossRef
149.
Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebocontrolled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41(12): 1597–607PubMedCrossRef
150.
Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, doubleblind, clinical trial. Neurology 2000; 54: 2245–51PubMedCrossRef
151.
Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195–204PubMedCrossRef
152.
Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451–60PubMedCrossRef
153.
154.
Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993; 34: 163–5PubMedCrossRef
155.
156.
Schmidt D, Arroyo S, Baulac M, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Seizure. Acta Neurol Scand 2001; 104: 167–70PubMedCrossRef
157.
Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993; 44: 529–33PubMedCrossRef
158.
Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998; 29: 109–14PubMedCrossRef
159.
Suzuki Y, Nagai T, Ono J, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997; 38: 1035–8PubMedCrossRef
160.
Kochak GM, Page JG, Buchanan RA, et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998; 38: 166–71PubMed
161.
Ojemann LM, Shastri RA, Wilensky AJ, et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986; 8(3): 293–6PubMedCrossRef
162.
Yamashita S, Furuno K, Moriyama M, et al. Effects of various antiepileptic drugs on plasma levels of lamotrigine, a novel antiepileptic, in rats. Pharmacology 1997; 54: 319–27PubMedCrossRef
163.
Tasaki K, Minami T, Ieiri I, et al. Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. Brain Dev 1995; 17: 182–5PubMedCrossRef
164.
Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67–73PubMedCrossRef
165.
Wilensky AJ, Friel PN, Ojemann LM, et al. Zonisamide in epilepsy: a pilot study. Epilepsia 1985; 26: 212–20PubMedCrossRef
166.
Kumagai N, Seki T, Yamawaki H, et al. Monotherapy for childhood epilepsies with zonisamide. Jpn J Psychiatry Neurol 1991; 45(2): 357–9PubMed
167.
Seino M, Miyazaki H, Ito T. Zonisamide. Epilepsy Res Suppl 1991; 3: 169–74PubMed
168.
Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000; 2(2): 99–105PubMed
169.
Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77–85PubMedCrossRef
170.
Kasteleijn-Nolst TD, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25: 225–30CrossRef
171.
Browne TR, Szabo GK, Leppik IE, et al. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 2000; 40(6): 590–5PubMedCrossRef
172.
Ben Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41(10): 1276–83PubMedCrossRef
173.
Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80–7PubMedCrossRef
174.
Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236–42PubMedCrossRef
175.
Neyens LG, Alpherts WC, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 411–9CrossRef
176.
The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29–33
177.
Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 1993; 43: 688–92PubMedCrossRef
178.
Richens A, Banfield CR, Salfi M, et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol 1997; 44: 129–34PubMedCrossRef
179.
Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38: 1265–9PubMedCrossRef
180.
O’Neil MG, Perdun CS, Wilson MB, et al. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996; 46: 1457–9PubMedCrossRef
181.
Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995; 45: 456–60PubMedCrossRef
182.
French J, Smith M, Faught E, et al. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999; 52(8): 1540–5PubMedCrossRef
183.
184.
Beran RG, Berkovic SF, Buchanan N, et al. A double-blind, placebo-controlled crossover study of vigabatrn 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 1996; 5: 259–65PubMedCrossRef
185.
Fejerman N, Cersosimo R, Caraballo R, et al. Vigabatrin as a first-choice drug in the treatment of West syndrome. J Child Neurol 2000; 15: 161–5PubMedCrossRef
186.
Ben-Menachem E, Persson L, Mumford J. Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy. Epilepsy Res 1990; 5: 240–6PubMedCrossRef
187.
Browne TR, Mattson RH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 1987; 37: 184–9PubMedCrossRef
188.
Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999; 354: 13–9PubMedCrossRef
189.
Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614–8PubMedCrossRef
190.
Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999; 53: 2082–7PubMedCrossRef
191.
Kalviainen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53(5): 922–6PubMedCrossRef
192.
Johnson MA, Krauss GL, Miller NR, et al. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000; 55: 40–5PubMedCrossRef
193.
Treiman DM. Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia 1989; 30Suppl. 2: S4–10PubMedCrossRef
194.
Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792–8PubMedCrossRef
195.
Bleck TP. Management approaches to prolonged seizures and status epilepticus. Epilepsia 1999; 40Suppl. 1: S59–63PubMedCrossRef
196.
O’Brien TJ, Cascino GD, So EL, et al. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology 1998 Oct; 51(4): 1034–9PubMedCrossRef
197.
Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996 Jun; 46(6 Suppl. 1): S3–7PubMedCrossRef
198.
Ramsay RE, DeToledo J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology 1996; 46: S17–9PubMedCrossRef
199.
Pryor FM, Gidal B, Ramsay RE, et al. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia 2001; 42(2): 245–50PubMedCrossRef
200.
Parent JM, Lowenstein H. Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology 1994; 44: 1837–40PubMedCrossRef
201.
Harper KW, Collier PS, Dundee JW, et al. Age and nature of operation influence the pharmacokinetics of midazolam. Br J Anaesth 1985; 57: 866–71PubMedCrossRef
202.
Smith MT, Heazlewood V, Eadie MJ, et al. Pharmacokinetics of midazolam in the aged. Eur J Clin Pharmacol 1984; 26: 381–8PubMedCrossRef
203.
Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000; 55: 722–4PubMedCrossRef
204.
Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999; 35(2): 147–53PubMedCrossRef
205.
Lühdorf K, Jensen LK, Plesner AM. Epilepsy in the elderly: incidence,social function and disability. Epilepsia; 1986; 27: 135–41PubMedCrossRef
206.
Hauser WA, Rich SS, Lee JR, et al. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998; 338: 429–34PubMedCrossRef
207.
Baker GA, Nashef L, van Hout BA. Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality. Epilepsia 1997; 38Suppl. 1: S1–8PubMedCrossRef
208.
Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. community study. Epilepsia 1996; 37: 148–61PubMedCrossRef
209.
Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999; 8: 339–42PubMedCrossRef
210.
211.
Ramsay E, Rowan AJ, Pryor FM, et al. Seizures in the older patient: demographics, diagnosis, and treatment [abstract]. Epilepsia 2000; 41Suppl. 7: 172
212.
Hauser WA, Rich SS, Annegers JF, et al. Seizure recurrence after a first unprovoked seizure: an extended follow-up. Neurology 1990; 40: 1163–70PubMedCrossRef
213.
Hart YM, Sander JW, Johnson AL, et al. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet 1990; 336: 1271–4PubMedCrossRef
214.
Rocca WA, Sharbrough FW, Hauser WA, et al. Risk factors for complex partial seizures: a population-based case-control study. Ann Neurol 1987; 21: 22–31PubMedCrossRef
215.
First Seizure Trial Group (FIR.S.T.Group). Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 1993; 43: 478–83
216.
Lühdorf K, Jensen K. Epilepsy in the elderly: prognosis. Acta Neurol Scand 1986; 74: 409–15PubMedCrossRef
217.
Elwes RDC, Johnson AL, Shorvon SD, et al. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984; 311: 944–77PubMedCrossRef
218.
Holt-Seitz A, Wirrell EC, Sundaram MB. Seizures in the elderly: etiology and prognosis. Can J Neurol Sci 1999; 26: 110–4PubMed
219.
Cameron H, Macphee GJ. Anticonvulsant therapy in the elderly — a need for placebo controlled trials. Epilepsy Res 1995; 21: 149–57PubMedCrossRef
220.
Johnson J, Pryor FM, Ramsay RE, et al. Clinical trials: recruitment challenges in the elderly [abstract]. Epilepsia 2000; 41Suppl. 7: 109
221.
Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41(11): 1364–74PubMedCrossRef
222.
Krämer G. Special features of individual antiepileptic drugs. In: Krämer G, editor. Epilepsy in the elderly. Stuttgart: Thieme Verlag, 1999: 75–103
223.
Cockerell OC, Johnson AL, Sander JW, et al. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997; 38: 31–46PubMedCrossRef
Metadaten
Titel
Treating Epilepsy in the Elderly
Safety Considerations
verfasst von
Dr Santiago Arroyo
Günter Kramer
Publikationsdatum
01.11.2001
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 13/2001
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124130-00006

Weitere Artikel der Ausgabe 13/2001

Drug Safety 13/2001 Zur Ausgabe

Correspondence

Lipid Abnormalities Induced by Novel Antipsychotic Drugs

Review Article

Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

Leading Article

Methods and Systems to Detect Adverse Drug Reactions in Hospitals

Leading Article

Therapeutic Drug Monitoring Databases for Postmarketing Surveillance of Drug-Drug Interactions

Current Opinion

Measles Vaccination and Inflammatory Bowel Disease

Review Article

Bodyweight Gain and Anticonvulsants